Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of an adsorbed acellular pertussis (two-component) combined diphtheria-tetanus vaccine in subjects aged ≥10 years
CTR20263005Phase 2Active
- Sponsor
- Changchun Baimu Biotechnology
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of diphtheria-tetanus vaccine + acellular pertussis vaccine in pertussis, diphtheria, Tetanus, sponsored by Changchun Baimu Biotechnology. Started Aug 2026; status: active.
02
Drugs
diphtheria-tetanus vaccine + acellular pertussis vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on CTR20263005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263005.